Home > Publications database > Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanoma. > print

001     300317
005     20250705113920.0
024 7 _ |a 10.1136/jitc-2024-010352
|2 doi
024 7 _ |a pmid:40210238
|2 pmid
037 _ _ |a DKFZ-2025-00763
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sun, Qian
|0 P:(DE-He78)f1f0076fc72606659a5df2605acce91b
|b 0
|e First author
|u dkfz
245 _ _ |a Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanoma.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1744364322_25914
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A370#LA:A370#
520 _ _ |a Neural crest-associated genes play pivotal roles in tumor initiation, progression, and the intricate dynamics of the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSC) within the TME are important in dampening T cell activity and contributing to resistance against immunotherapeutic interventions. The neural crest-associated gene Forkhead Box D1 (FOXD1) has been identified as an oncogenic factor that induces melanoma dedifferentiation and progression. However, the underlying mechanisms and the impact of FOXD1 on the antitumor immune response remain unclear.To investigate the impacts of FOXD1 on the melanoma microenvironment, we analyzed publicly available datasets from multiple platforms, including TNMplot, TIMER2.0, etc. In addition, FOXD1 was overexpressed (OE) or knocked down in melanoma cells to identify its biological functions in vitro and in vivo. Flow cytometry and arginase activity assay were used to analyze the phenotype and function of MDSC. Western blot, reverse transcription-PCR, or ELISA assays were employed to analyze the expression of FOXD1 and its downstream effectors. In vivo experiments were conducted to investigate the role of FOXD1 in melanoma progression and the influence on MDSC accumulation within the TME.We demonstrate that increased FOXD1 levels inversely correlated with melanoma responsiveness to immunotherapy. Ex-vivo analyses unveiled that monocytes, exposed to conditioned medium from FOXD1-OE melanoma cells, effectively suppressed T cell proliferation and upregulated the expression of programmed death-ligand 1 (PD-L1) and other immunosuppressive factors. FOXD1 was identified as a direct regulator of interleukin 6 (IL6) expression, which is pivotal for MDSC induction. Blocking IL6 reversed MDSC-associated immunosuppression. Additionally, miR-581, a potential negative regulator of FOXD1, attenuated the impact of FOXD1 on IL6 expression and MDSC differentiation. In vivo experiments demonstrated that tumors derived from FOXD1 OE melanoma cells contained a significantly higher frequency of PD-L1+ MDSC compared with controls, while FOXD1 knockdown resulted in reduced tumor growth and diminished MDSC accumulation.Our study elucidated a novel function of FOXD1 in melanoma pathogenesis, highlighting its role in orchestrating the immunosuppressive TME by promoting the generation of MDSC via IL6 upregulation.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Immunosuppression
|2 Other
650 _ 7 |a Myeloid-derived suppressor cell - MDSC
|2 Other
650 _ 7 |a Skin Cancer
|2 Other
650 _ 7 |a Tumor microenvironment - TME
|2 Other
650 _ 7 |a Forkhead Transcription Factors
|2 NLM Chemicals
650 _ 7 |a FOXD1 protein, human
|2 NLM Chemicals
650 _ 2 |a Myeloid-Derived Suppressor Cells: immunology
|2 MeSH
650 _ 2 |a Myeloid-Derived Suppressor Cells: metabolism
|2 MeSH
650 _ 2 |a Melanoma: genetics
|2 MeSH
650 _ 2 |a Melanoma: pathology
|2 MeSH
650 _ 2 |a Melanoma: immunology
|2 MeSH
650 _ 2 |a Melanoma: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Forkhead Transcription Factors: metabolism
|2 MeSH
650 _ 2 |a Forkhead Transcription Factors: genetics
|2 MeSH
650 _ 2 |a Tumor Microenvironment: immunology
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Neural Crest: metabolism
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
700 1 _ |a Wang, Nina
|0 P:(DE-He78)f3d19b02f83230d528305e528fcd72c8
|b 1
|u dkfz
700 1 _ |a Poelchen, Juliane
|0 P:(DE-He78)88a268b9173c651561385cddfdf819fa
|b 2
700 1 _ |a Peter, Mareike
|0 P:(DE-He78)546bfa827219c21271966448a4321e61
|b 3
700 1 _ |a Novak, Daniel
|0 P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758
|b 4
|u dkfz
700 1 _ |a Özbay Kurt, Feyza Gül
|0 P:(DE-He78)1784bfc87359b14c283e6b02cabca28d
|b 5
|u dkfz
700 1 _ |a Bitsch, Rebekka
|0 P:(DE-He78)d56d42ddfa25c8d79cba10aed608b0df
|b 6
700 1 _ |a Wu, Huizi
|0 P:(DE-He78)09029e5d1361b4ff0c0e9ca28c5c9943
|b 7
700 1 _ |a Wang, Yiman
|0 P:(DE-He78)ada7e359a1f7451130dbc79595227bec
|b 8
700 1 _ |a Pardo, Sandra
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Han, Rui
|0 0009-0004-8843-9938
|b 10
700 1 _ |a Liu, Shibo
|b 11
700 1 _ |a Gong, Lidong
|b 12
700 1 _ |a Zhang, Yuxin
|0 P:(DE-He78)66623fe2fa2e29982369f4d828fec9bd
|b 13
|u dkfz
700 1 _ |a Wistuba-Hamprecht, Kilian
|0 P:(DE-He78)9512bd1a1d23a9812ab49fafcfa56ebf
|b 14
|u dkfz
700 1 _ |a Umansky, Viktor
|0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
|b 15
|u dkfz
700 1 _ |a Utikal, Jochen
|0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|b 16
|e Last author
|u dkfz
773 _ _ |a 10.1136/jitc-2024-010352
|g Vol. 13, no. 4, p. e010352 -
|0 PERI:(DE-600)2719863-7
|n 4
|p e010352
|t Journal for ImmunoTherapy of Cancer
|v 13
|y 2025
|x 2051-1426
909 C O |o oai:inrepo02.dkfz.de:300317
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)f1f0076fc72606659a5df2605acce91b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f3d19b02f83230d528305e528fcd72c8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)88a268b9173c651561385cddfdf819fa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)546bfa827219c21271966448a4321e61
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)1784bfc87359b14c283e6b02cabca28d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)d56d42ddfa25c8d79cba10aed608b0df
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)09029e5d1361b4ff0c0e9ca28c5c9943
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)ada7e359a1f7451130dbc79595227bec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)66623fe2fa2e29982369f4d828fec9bd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)9512bd1a1d23a9812ab49fafcfa56ebf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J IMMUNOTHER CANCER : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-24T13:16:43Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-24T13:16:43Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-24T13:16:43Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J IMMUNOTHER CANCER : 2022
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 2 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
920 1 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
920 0 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A370-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21